a study to test the combination of two different kinds of medications for the treatment of diabetes

Conditions: Diabetes Mellitus, Type 2

Summary: test the safety, tolerability and improvement of blood sugar control with combination therapy in individuals with type 2 diabetes.


Eligibility criteria:
inclusion criteria: * written informed consent * have type 2 diabetes mellitus (t2dm) for at least 6 months * currently treated with diet and exercise alone or in combination with stable metformin * glycosylated hemoglobin (hba1c) 7.0% to 10.0% * ages 18 to 70 years * women not of childbearing potential * body mass index (bmi) between 25 and 40 kilograms per meters squared (kg/m\^2), and stable weight in the 3 months prior to screening. exclusion criteria: * use of diabetes medicine other than metformin in past 3 months * gastrointestinal disease or surgery or drugs that significantly impacts gastric filling, emptying or motility; ongoing cholelithiasis or cholecystitis. * chronic, daily proton pump inhibitors (ppis) and histamine (h2) antagonists. * severe hypoglycemia or hyperglycemia * advanced microvascular diabetes complications * medications to promote weight loss. * breastfeeding women * cardiac autonomic neuropathy * in the past 6 months have cardiac disease with functional status that is class ii-iv or a history of myocardial infarction, unstable angina, coronary artery bypass graft, percutaneous coronary intervention, transient ischemic attack, cerebrovascular accident (stroke), or decompensated congestive heart failure. * history of a supraventricular or ventricular tachycardia, pacemaker implantation, or other cardiac arrhythmia: poorly controlled hypertension, malignant hypertension, renal artery stenosis, and/or evidence of labile blood pressure including symptomatic postural hypotension. * electrocardiograms (ecg) abnormality or medication that impairs the ability to measure qt interval (qt), or correct the qt interval (qt) for rate. * qt interval bazett corrected (qtcb) \>450 milliseconds (msec) or pr interval (pr) \>220 milliseconds (msec) * personal or family history of long qt interval (qt) syndrome, sudden death, or unexplained syncope * clinical signs or symptoms of liver disease, acute or chronic hepatitis, or alanine transaminase levels \> 2.5 times the upper limit of the reference range * hypertriglyceridemia \> 400 mg/deciliter (dl) * inadequately treated hypothyroidism or hyperthyroidism * peptic ulcer disease and/or gastrointestinal bleeding/perforation. * known pentagastrin hypersensitivity * impaired renal function * transplanted organ. * active, uncontrolled endocrine or autoimmune abnormality * \> 2 weeks systemic glucocorticoid therapy * ongoing courses of non-steroidal anti-inflammatory drugs (nsaids), except for aspirin 81-325 milligrams (mg) * diagnosed malignancy or in remission for less than 5 years. * prior acute or chronic pancreatitis or elevated serum lipase or amylase * current central nervous system stimulant * other conditions that preclude the participant from participating, following or completing the protocol. * chronic infection * personnel affiliated with the study and their immediate families. * within 30 days of the initial dose of study drug, have participated in an interventional medical, surgical, or pharmaceutical study in which a medical or surgical treatment was given. * have previously completed or withdrawn from this study after providing informed consent. * are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an off-label use of an investigational drug or device (other than the study drug/device used in this study), or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.